Supplementary Table 1. Summary of Studies and Patient Characteristics

	101-08, Cohort 1 (NCT01203930)	101-08, Cohort 2 (NCT01203930)	312-0123 (NCT01980888)	312-0133 (NCT002044822)	312-0116 (NCT01539512)	312-0119 (NCT01659021)	312-0115 (NCT01569295)	All N=853
Eligibility criteria	**Untreated CLL Aged ≥65 y**	**Untreated CLL Aged ≥65 y**	**Untreated CLL**	**Untreated CLL with del(17p)**	**R/R CLL**	**R/R CLL**	**R/R CLL**	
Treatment	**IDELA + R**	**IDELA**	**IDELA + BR**	**IDELA + R**	**IDELA + R**	**IDELA + O**	**IDELA + BR**	
Patients on IDELA, n	**64**	**41**	**156**	**102**	**110**	**173**	**207**	
Median IDELA exposure (range) – mos.	**10.8** (0.8, 12.3)	**9.3** (1.4, 26.8)	**12.1** (0.2, 22.1)	**6.4** (0.7, 17.0)	**8.1** (0.3, 19.5)	**13.9** (0.2, 36.5)	**18.2** (0, 43.4)	**11** (<1, 43)
Median age (range), y	**71** (65, 90)	**71** (65, 84)	**65** (37, 83)	**66** (37, 86)	**71** (48, 90)	**68** (40, 85)	**62** (38, 83)	**67** (37, 90)
Number of prior regimens (range)	**N/A**	**N/A**	**N/A**	**N/A**	**3.0** (1, 12)	**3.0** (1, 11)	**2.0** (1, 13)	**R/R n=490**
Unmutated, %	**58**	**46**	**65**	**87**	**83**	**79**	**84**	
Del (17p), %	**9**	**10**	**6**	**100**	**24**	**27**	**18**	
Patients with Grade ≥3 ALT/AST elevation, n (%)	**15** (23)	**9** (22)	**41** (26)	**42** (41)	**10** (9)	**22** (13)	**47** (23)	
PBO-treated patients with Grade ≥3 ALT/AST elevation, n (%)	**N/A**	**N/A**	**2/154** (1.3)	**N/A**	**1/108** (0.9)	**1/86** (1.2)	**8/209** (3.8)	**N/A**

ALT, alanine transaminase; AST, aspartate transaminase